Criteria of the European Organization for Research and Treatment of Cancer Groupe d'Eude des Lymphomes de l'Adulte (EORTC-GELA) for Favorable Prognostic Groups of Hodgkin's Disease
The European Organization for Research and Treatment of Cancer and Groupe d'Eude des Lymphomes de l'Adulte (EORTC-GELA) have identified prognostic factors associated with favorable and very favorable outcomes in patients with Hodgkin's disease. This can help determine how intensive of a therapeutic regimen is required for management.
Parameters
Very Favorable: all of the following
Favorable: all of the following
age
< 40 (16 – 39)
< 50 (16 – 49)
gender
female
male or female
Clinical Stage (Ann Arbor)
I
I or II
B symptoms
none (clinical A)
(see ESR)
histology
lymphocyte predominant or nodular sclerosing
lymphocyte predominant or nodular sclerosing
erythrocyte sedimentation rate (ESR)
< 50 mm in first hour
ESR < 50 AND no B symptoms; ESR AND B symptoms present
bulky disease
absent
absent
number of lymph node regions involved
1 (definition of CS I)
< 4
where:
• Criteria for Ann Arbor staging and clinical symptoms are given above, under non-Hodgkin's lymphoma.
• The gender for the favorable group was not specified, but males are listed in Table 1, page 1732 of Wilder et al.
To read more or access our algorithms and calculators, please log in or register.
